步长制药子公司起诉捷迈上海公司，涉案6.52亿元

Core Viewpoint - The lawsuit filed by Shanghai HePu Medical Technology Co., Ltd., a subsidiary of BuChang Pharmaceutical, against JEM International Trade (Shanghai) Co., Ltd. involves a contract dispute over an amount of 652 million yuan, primarily concerning unsold inventory and financial losses [1][2]. Group 1: Lawsuit Details - Shanghai HePu has initiated legal action against JEM Shanghai for a contract dispute, claiming an amount of 652 million yuan [1]. - The lawsuit arises from a distribution agreement where Shanghai HePu was an authorized distributor for JEM Shanghai, which is a subsidiary of the well-known orthopedic consumables company JEM [1]. - The lawsuit requests JEM Shanghai to repurchase approximately 556 million yuan worth of remaining inventory and return a prepayment of 3.2078 million yuan, along with compensation for interest losses and other costs [1]. Group 2: Inventory and Financial Implications - Shanghai HePu has around 550 million yuan worth of inventory that has not been transferred to a new authorized distributor, with no clear plan for the transfer [1]. - There is a risk of inventory impairment for the 550 million yuan worth of stock, which could impact the company's current and future profits, although the exact financial impact remains uncertain [2].